<?xml version="1.0" encoding="UTF-8"?>
<p>Next, we tested the effect of regorafenib and sorafenib on susceptibility of primary human airway epithelial cells from bronchi (hAECB). We used the same dose as with A549 cells, 3 μM, a dose not cytotoxic for hAECB cells (
 <xref ref-type="supplementary-material" rid="ppat.1007601.s009">S9B Fig</xref>). Also in primary cells, UBKIs efficiently blocked viral protein expression (
 <xref ref-type="fig" rid="ppat.1007601.g006">Fig 6C</xref>). Then, we assessed both UBKIs effects on viral replication in hAECB cells. To this end, we employed the highest dose without detectable cytotoxicity to hAECB cells, 5 μM (
 <xref ref-type="supplementary-material" rid="ppat.1007601.s009">S9B and S9D Fig</xref>). Again, both inhibitors revealed a significant reduction of virus replication, although the effect induced by regorafenib was found to be more pronounced, especially at later time points (
 <xref ref-type="fig" rid="ppat.1007601.g006">Fig 6D</xref>).
</p>
